Focus Funding News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Focus funding. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Focus Funding Today - Breaking & Trending Today
Outcome of the largest interdisciplinary call for proposals to date / Topics ranging from aerosol formation in the lungs to global causes and science communication / Funding totals €31.5 million. ....
DFG establishes “COVID-19 Focus Funding” to address questions on coronavirus pandemic The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) has made its first decisions in the new COVID-19 Focus Funding instrument. These decisions will enable 33 projects to immediately begin research on immunity, host susceptibility, and pathomechanisms of infection with SARS-CoV-2. A total of €3.6 million will be provided for a maximum of one year, including the standard program allowance for indirect project costs. COVID-19 Focus Funding was set up by the DFG in August of this year in the Research Grants Programme to enable researchers to address particularly urgent questions on the coronavirus pandemic that need short-term answers. ....
E-Mail The most promising vaccine against the coronavirus to date is also an example of the long-term value of curiosity-driven basic research and its funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation). The so-called mRNA vaccine platform, which the Mainz-based company BioNTech uses in its Covid-19 vaccine developed jointly with the US pharmaceutical company Pfizer, can be traced back to preliminary work carried out from 2006 to 2008 in a project within a DFG-funded Collaborative Research Centre (CRC) on cancer research at the Johannes Gutenberg University Mainz. This in turn was also tied to previous DFG-funded research. The project was led by the later founder and current CEO of BioNTech, Professor Dr. U?ur ?ahin, whose name and person are closely associated with the development of the BNT162b2 vaccine, which will be deployed immediately following its approval in the United Kingdom and its anticipated approval in the USA and the EU. In ad ....